FDA’s medication errors director to retire
Executive Summary
FDA Office of Drug Safety Medication Errors Prevention Associate Director Jerry Phillips is leaving to become president of the Drug Safety Institute. Phillips' May departure will likely coincide with the anticipated release of a guidance on submission of proprietary brand names (1"The Pink Sheet" Dec. 8, 2003, p. 35)...
You may also be interested in...
FDA Drug Name Guidance Is “Premature” Without More Data, Cmte. Says
Development of an FDA guidance on how to screen proprietary drug names for potential medication errors would be premature without more outcomes data, the Drug Safety & Risk Management Advisory Committee agreed Dec. 4
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.